Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
(ANTX) stock logo
ANTX
(ANTX)
$1.11
-9.4%
$0.00
$0.87
$3.07
$33.76M0.15366,658 shs83,337 shs
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$17.14
+0.4%
$13.15
$7.75
$19.93
$130.45M0.5526,240 shs18,229 shs
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$8.92
-1.2%
$9.62
$8.06
$18.15
$120.72M1.6946,222 shs34,228 shs
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
$2.70
+10.2%
$3.51
$1.80
$7.93
$107.02M0.23232,138 shs138,592 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
(ANTX) stock logo
ANTX
(ANTX)
-6.36%-3.49%-5.56%-24.05%-44.75%
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
+0.35%+0.53%+24.20%+60.34%+15.19%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-1.22%-7.37%-12.38%-21.34%-44.15%
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
+10.20%+1.50%-28.38%-32.50%+269,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/AN/AN/AN/AN/A
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
4.0202 of 5 stars
3.35.00.04.71.40.80.0
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
2.0239 of 5 stars
3.51.00.00.00.03.30.0
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
1.698 of 5 stars
3.60.00.00.02.90.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
(ANTX) stock logo
ANTX
(ANTX)
2.00
Hold$1.5035.75% Upside
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
2.67
Moderate Buy$33.0092.53% Upside
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
3.00
Buy$39.00337.22% Upside
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
3.25
Buy$12.67369.14% Upside

Current Analyst Ratings Breakdown

Latest ANTX, GLSI, ASMB, and HURA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
5/5/2025
(ANTX) stock logo
ANTX
(ANTX)
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$5.00 ➝ $2.00
4/21/2025
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$38.00 ➝ $39.00
4/3/2025
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $12.00
3/25/2025
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$31.00
3/24/2025
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/A$4.19 per shareN/A
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$28.52M4.59N/AN/A$5.25 per share3.26
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/A$0.19 per shareN/A
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/AN/AN/AN/A$0.34 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
(ANTX) stock logo
ANTX
(ANTX)
-$64.73M-$2.04N/AN/AN/AN/A-57.62%-52.08%N/A
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$40.18M-$6.23N/AN/AN/A-124.15%-131.77%-36.81%8/6/2025 (Estimated)
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$15.79M-$1.26N/AN/AN/AN/A-450.87%-333.18%8/12/2025 (Estimated)
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
-$21.68MN/A0.00N/AN/A291.69%122.09%N/A

Latest ANTX, GLSI, ASMB, and HURA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2025Q1 2025
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.24-$0.25-$0.01-$0.25N/AN/A
5/15/2025Q1 2025
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
-$0.13-$0.15-$0.02-$0.15N/AN/A
5/8/2025Q1 2025
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$2.01-$1.17+$0.84-$1.17$7.41 million$9.42 million
4/15/2025Q4 2024
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.21-$0.61-$0.40-$0.61N/AN/A
3/20/2025Q4 2024
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$1.75-$1.57+$0.18-$1.57$7.05 million$7.36 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/AN/A
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/AN/AN/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/AN/A
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
(ANTX) stock logo
ANTX
(ANTX)
N/A
9.75
9.75
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/A
2.05
2.05
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A
1.91
1.91
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/A
3.00
3.00

Institutional Ownership

CompanyInstitutional Ownership
(ANTX) stock logo
ANTX
(ANTX)
90.47%
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
19.92%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
4.16%
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
0.62%

Insider Ownership

CompanyInsider Ownership
(ANTX) stock logo
ANTX
(ANTX)
20.79%
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
5.30%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
51.67%
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
0.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
(ANTX) stock logo
ANTX
(ANTX)
N/A29.88 million23.67 millionNot Optionable
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
1007.64 million7.23 millionOptionable
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
313.37 million6.46 millionNot Optionable
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/A43.68 million43.59 millionN/A

Recent News About These Companies

TuHURA Biosciences Amid Nasdaq Composite Volatility

New MarketBeat Followers Over Time

Media Sentiment Over Time

(ANTX) stock logo

(ANTX) NYSE:ANTX

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Assembly Biosciences stock logo

Assembly Biosciences NASDAQ:ASMB

$17.14 +0.06 (+0.35%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$17.18 +0.04 (+0.20%)
As of 06/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Greenwich LifeSciences stock logo

Greenwich LifeSciences NASDAQ:GLSI

$8.92 -0.11 (-1.22%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$9.27 +0.35 (+3.97%)
As of 06/18/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

TuHURA Biosciences stock logo

TuHURA Biosciences NASDAQ:HURA

$2.70 +0.25 (+10.20%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$2.58 -0.12 (-4.44%)
As of 06/18/2025 07:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.